US FDA approves Santhera's Duschenne drug

Santhera Pharmaceuticals Holding AG

26/10/2023 20:19

Oct 26 (Reuters) - The U.S. Food and Drug Administration
said on Thursday it has approved Santhera Pharmaceuticals'
 SANN.S  drug to treat Duchenne muscular dystrophy (DMD), a rare
muscle-wasting disorder, in patients two years of age and older.

 (Reporting by Leroy Leo and Khushi Mandowara in Bengaluru;
Editing by Maju Samuel)
 ((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;))